UA115686C2 - Хіназолінові інгібітори активувальних мутантних форм рецептора епідермального фактора росту - Google Patents

Хіназолінові інгібітори активувальних мутантних форм рецептора епідермального фактора росту

Info

Publication number
UA115686C2
UA115686C2 UAA201508063A UAA201508063A UA115686C2 UA 115686 C2 UA115686 C2 UA 115686C2 UA A201508063 A UAA201508063 A UA A201508063A UA A201508063 A UAA201508063 A UA A201508063A UA 115686 C2 UA115686 C2 UA 115686C2
Authority
UA
Ukraine
Prior art keywords
mutant forms
growth factor
factor receptor
epidermal growth
activating mutant
Prior art date
Application number
UAA201508063A
Other languages
English (en)
Inventor
Дейвід Юньчжі Лі
Цзябін Ван
Чженьфан Ян
Цінбей Цзен
Сяолінь Чжан
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115686(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of UA115686C2 publication Critical patent/UA115686C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Винахід стосується сполук формули (І) або їх фармацевтично прийнятної солі: EMBED ISISServer (I), які мають інгібіторну активність проти активувальних мутантних форм EGFR, та, відповідно, є корисними щодо їх активності проти раку, та способів лікування людини або організму тварини. Винахід також стосується фармацевтичних композицій, які їх містять, та їх застосування у виготовленні медикаментів для застосування в отриманні дії проти раку в теплокровної тварини, як-то людина.
UAA201508063A 2013-03-06 2014-03-05 Хіназолінові інгібітори активувальних мутантних форм рецептора епідермального фактора росту UA115686C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013072250 2013-03-06
PCT/GB2014/050655 WO2014135876A1 (en) 2013-03-06 2014-03-05 Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor

Publications (1)

Publication Number Publication Date
UA115686C2 true UA115686C2 (uk) 2017-12-11

Family

ID=50288181

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201508063A UA115686C2 (uk) 2013-03-06 2014-03-05 Хіназолінові інгібітори активувальних мутантних форм рецептора епідермального фактора росту

Country Status (42)

Country Link
US (4) US9066979B2 (uk)
EP (2) EP3342770B1 (uk)
JP (1) JP5894714B1 (uk)
KR (1) KR101645112B1 (uk)
CN (1) CN105209456B (uk)
AP (1) AP2015008696A0 (uk)
AR (1) AR095039A1 (uk)
AU (1) AU2014224382B2 (uk)
BR (1) BR112015020787B1 (uk)
CA (1) CA2901269C (uk)
CL (1) CL2015002361A1 (uk)
CR (1) CR20150450A (uk)
CY (1) CY1119487T1 (uk)
DK (1) DK2964638T3 (uk)
DO (1) DOP2015000189A (uk)
ES (1) ES2642201T3 (uk)
GT (1) GT201500251A (uk)
HK (1) HK1216315A1 (uk)
HR (1) HRP20171689T1 (uk)
HU (1) HUE034568T2 (uk)
IL (1) IL240578B (uk)
LT (1) LT2964638T (uk)
MA (1) MA38380A1 (uk)
ME (1) ME03041B (uk)
MX (1) MX362247B (uk)
MY (1) MY186126A (uk)
NI (1) NI201500123A (uk)
NO (1) NO2964638T3 (uk)
PE (1) PE20152000A1 (uk)
PH (1) PH12015501965B1 (uk)
PL (1) PL2964638T3 (uk)
PT (1) PT2964638T (uk)
RS (1) RS56566B1 (uk)
RU (1) RU2656597C2 (uk)
SG (1) SG11201506487YA (uk)
SI (1) SI2964638T1 (uk)
TN (1) TN2015000368A1 (uk)
TW (1) TWI543977B (uk)
UA (1) UA115686C2 (uk)
UY (1) UY35369A (uk)
WO (1) WO2014135876A1 (uk)
ZA (1) ZA201507353B (uk)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014224382B2 (en) * 2013-03-06 2016-11-10 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
JP6559132B2 (ja) 2013-08-23 2019-08-14 ニューファーマ， インコーポレイテッド ある特定の化学的実体、組成物および方法
WO2016051380A1 (en) * 2014-10-01 2016-04-07 Sun Pharmaceutical Industries Limited Crystalline form of afatinib dimaleate
WO2016133935A1 (en) 2015-02-17 2016-08-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN105859641B (zh) 2015-05-05 2018-11-16 杭州华东医药集团新药研究院有限公司 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
CN105503905B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物b晶型及其制备方法
CN105503906B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物a晶型及其制备方法
CA3033370A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN108658946B (zh) * 2017-03-28 2020-06-16 焦玉奇 新颖的喹唑啉抑制剂
CN107400094B (zh) * 2017-09-08 2020-04-03 贾玉庆 喹唑啉基羧酸酯类化合物及其用途
CN109721552B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种吉非替尼的制备方法
CN109721551B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种3,4-二氢-7-甲氧基-4-氧代喹唑啉-6-醇乙酸酯的制备方法
US11465975B2 (en) 2018-02-08 2022-10-11 Neupharma, Inc Certain chemical entities, compositions, and methods
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
AU2019340598A1 (en) * 2018-09-14 2021-03-18 Hanmi Pharmaceutical Co., Ltd. Crystalline forms of a quinazole compound and its hydrochloride salts
CN110903283B (zh) * 2018-09-17 2021-01-01 南京雷正医药科技有限公司 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
WO2020057403A1 (zh) * 2018-09-18 2020-03-26 北京越之康泰生物医药科技有限公司 吲哚衍生物及其在医药上的应用
CA3133766A1 (en) 2019-03-29 2020-10-08 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
CN110590683B (zh) * 2019-10-11 2022-08-19 山东四环药业股份有限公司 一种靶向药物azd3759中间体的制备方法
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN111675700A (zh) * 2020-06-22 2020-09-18 通化师范学院 一种抗癌新药azd3759的制备方法
CN111662273A (zh) * 2020-06-22 2020-09-15 通化师范学院 一种酪氨酸激酶抑制剂azd3759的制备方法
CN111848584A (zh) * 2020-07-10 2020-10-30 江南大学 一种多取代喹唑啉类化合物及其应用
CN113943273A (zh) * 2020-07-17 2022-01-18 上海天慈国际药业有限公司 一种肺癌药物azd3759的制备方法
CN113135901A (zh) * 2021-04-12 2021-07-20 南京雷正医药科技有限公司 氘代的喹唑啉类盐酸盐化合物的晶型及其制备和应用
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN115813927A (zh) * 2022-07-06 2023-03-21 江苏晨泰医药科技有限公司 受体酪氨酸激酶抑制剂与联苯环辛二稀木脂素的联合用药及其用途
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
DE69939526D1 (de) 1998-02-24 2008-10-23 Sisters Of Providence In Orego Zusammensetzungen, die entweder ein ox-40-rezeptor-bindemittel oder eine für ein solches bindemittel kodierende nukleicsäuresequenz enthalten, und verfahren zur verbesserung der antigenspezifischen immunantwort
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TR200200749T2 (tr) 1999-09-21 2002-06-21 Astrazeneca Ab Kinazolin bileşikleri ve bunları içeren farmasötik bileşikler.
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
MXPA04009536A (es) * 2002-03-30 2005-01-25 Boehringer Ingelheim Pharma Compuestos heterociclos biciclicos, composiciones farmaceuticas que contienen estos compuestos, su utilizacion y procesos para su preparacion.
US7550140B2 (en) 2002-06-13 2009-06-23 Crucell Holland B.V. Antibody to the human OX40 receptor
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
JP2007500177A (ja) 2003-07-29 2007-01-11 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのピペリジルキナゾリン誘導体
CA2541100A1 (en) 2003-09-16 2005-03-24 Astrazenca Ab Quinazoline derivatives
DE602004004811T2 (de) 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
CA2538752C (en) 2003-09-19 2011-08-02 Astrazeneca Ab Quinazoline derivatives
WO2005097137A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
KR101347613B1 (ko) 2004-03-31 2014-01-06 다나-파버 캔서 인스티튜트 인크. 암에 걸린 인간 환자의 표피성장인자 수용체 표적 치료의 유효 가능성 결정 방법, 키트, 핵산 프로브 및 프라이머쌍
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN101175732B (zh) 2005-05-12 2010-06-16 黄文林 一种喹唑啉衍生物的制备方法及用作制备治疗肿瘤疾病药物的应用
WO2006119676A1 (fr) 2005-05-12 2006-11-16 Wenlin Huang Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d'une maladie tumorale
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
JP2009506990A (ja) 2005-08-22 2009-02-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式複素環、これら化合物を含む医薬、それらの使用及びそれらの製造方法
PT1971601E (pt) * 2005-11-15 2010-01-26 Array Biopharma Inc Derivados de n4-fenil-quinazolina-4-amina e compostos relacionados como inibidores de tirosina quinases receptoras do tipo i erbb para o tratamento de doenças hiperproliferativas
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
BRPI0602275A (pt) 2006-03-24 2007-11-27 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e processo para a preparação de um derivado de quinalizona
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CN101367793B (zh) 2008-09-26 2013-09-11 中国科学院广州生物医药与健康研究院 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
WO2010061208A2 (en) 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
KR101934071B1 (ko) 2009-11-24 2019-01-02 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
PE20160588A1 (es) 2009-12-31 2016-07-09 Hutchison Medipharma Ltd Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
CN101857618B (zh) 2010-06-13 2015-11-25 中国海洋大学 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物，其制备方法和应用
EP2609118B1 (en) 2010-08-23 2017-01-18 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
AU2014224382B2 (en) * 2013-03-06 2016-11-10 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor

Also Published As

Publication number Publication date
LT2964638T (lt) 2017-12-27
IL240578A0 (en) 2015-09-24
SI2964638T1 (sl) 2017-11-30
US20140255428A1 (en) 2014-09-11
PE20152000A1 (es) 2016-01-22
HK1216315A1 (zh) 2016-11-04
US20160340342A1 (en) 2016-11-24
PT2964638T (pt) 2017-11-14
AU2014224382B2 (en) 2016-11-10
ME03041B (me) 2018-10-20
WO2014135876A1 (en) 2014-09-12
CN105209456A (zh) 2015-12-30
NO2964638T3 (uk) 2018-01-06
US9718806B2 (en) 2017-08-01
RU2656597C2 (ru) 2018-06-06
ZA201507353B (en) 2017-03-29
CL2015002361A1 (es) 2016-01-04
EP3342770A1 (en) 2018-07-04
KR101645112B1 (ko) 2016-08-02
JP5894714B1 (ja) 2016-03-30
RU2015139513A (ru) 2017-04-10
ES2642201T3 (es) 2017-11-15
NZ710850A (en) 2020-09-25
TW201520206A (zh) 2015-06-01
BR112015020787B1 (pt) 2022-12-06
PL2964638T3 (pl) 2018-01-31
CA2901269A1 (en) 2014-09-12
CA2901269C (en) 2022-01-18
KR20150083782A (ko) 2015-07-20
AU2014224382A1 (en) 2015-09-03
BR112015020787A2 (pt) 2017-07-18
DK2964638T3 (en) 2017-10-30
EP2964638B1 (en) 2017-08-09
US20180016259A1 (en) 2018-01-18
PH12015501965A1 (en) 2016-01-11
HUE034568T2 (en) 2018-02-28
TWI543977B (zh) 2016-08-01
CY1119487T1 (el) 2018-03-07
PH12015501965B1 (en) 2016-01-11
IL240578B (en) 2019-03-31
MY186126A (en) 2021-06-24
US9375432B2 (en) 2016-06-28
CN105209456B (zh) 2018-05-08
US20150320751A1 (en) 2015-11-12
CR20150450A (es) 2015-12-01
JP2016511225A (ja) 2016-04-14
MX2015011818A (es) 2016-01-08
MX362247B (es) 2019-01-09
EP3342770B1 (en) 2022-03-30
EP2964638A1 (en) 2016-01-13
TN2015000368A1 (en) 2017-01-03
UY35369A (es) 2014-08-29
SG11201506487YA (en) 2015-09-29
US9066979B2 (en) 2015-06-30
MA38380A1 (fr) 2017-01-31
HRP20171689T1 (hr) 2018-02-23
DOP2015000189A (es) 2015-08-31
AR095039A1 (es) 2015-09-16
RS56566B1 (sr) 2018-02-28
GT201500251A (es) 2017-10-09
NI201500123A (es) 2016-02-16
AP2015008696A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
PH12015501965A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
MX343706B (es) Derivados heterocíclicos novedosos.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MY174188A (en) Heterocyclyl compounds
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
TN2012000067A1 (en) Oxazine derivatives and their use in the treatment of neurological disorders
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
MY181828A (en) Bicyclically substituted uracils and the use therapy
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
IN2015MN00045A (uk)
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
MY192305A (en) Bipyrazole derivatives as jak inhibitors
TN2013000327A1 (en) Novel heterocyclic derivatives